187 related articles for article (PubMed ID: 1353465)
1. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
Brzozowski T; Majka J; Konturek SJ
Digestion; 1992; 51(1):27-36. PubMed ID: 1353465
[TBL] [Abstract][Full Text] [Related]
2. Prevention and healing of experimental indomethacin-induced gastric lesions: effects of ebrotidine, omeprazole and ranitidine.
Arroyo MT; Lanas A; Sáinz R
Eur J Gastroenterol Hepatol; 2000 Mar; 12(3):313-8. PubMed ID: 10750652
[TBL] [Abstract][Full Text] [Related]
3. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
4. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
5. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
[TBL] [Abstract][Full Text] [Related]
6. Ebrotidine.
Patel SS; Wilde MI
Drugs; 1996 Jun; 51(6):974-80; discussion 981. PubMed ID: 8736619
[TBL] [Abstract][Full Text] [Related]
7. Effect of ebrotidine on gastric mucosal EGF and PDGF receptor expression.
Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A; Slomiany BL
Biochem Mol Biol Int; 1993 Aug; 30(6):1127-34. PubMed ID: 8106073
[TBL] [Abstract][Full Text] [Related]
8. Gastric mucosal EGF and PDGF receptor expression with ulcer healing by ebrotidine.
Slomiany BL; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
Am J Gastroenterol; 1994 Jun; 89(6):894-7. PubMed ID: 8198101
[TBL] [Abstract][Full Text] [Related]
9. Gastroprotective properties of ebrotidine. A review.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ebrotidine and ranitidine in the treatment of benign gastric ulcer.
Gedliczka O; Bobrzynski A; Rembiasz K; Fillat O; Torres J; Herrero E; Márquez M; Camps F; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):560-4. PubMed ID: 9205765
[TBL] [Abstract][Full Text] [Related]
11. Gastroprotective and antisecretory effects of ebrotidine.
Konturek SJ; Maczka J; Kaminski K; Sito E; Torres J; Oleksy J
Scand J Gastroenterol; 1992 Jun; 27(6):438-42. PubMed ID: 1352908
[TBL] [Abstract][Full Text] [Related]
12. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ebrotidine compared with ranitidine in patients with duodenal ulcer.
Gabryelewicz A; Konturek SJ; Butruk E; Dzieniszewski J; Marlicz K; Nowak A; Torres J; Marquez M; Ortiz JA
Eur J Gastroenterol Hepatol; 1995 Apr; 7(4):361-6. PubMed ID: 7600143
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of the safety and efficacy of ebrotidine versus ranitidine and placebo in the prevention of piroxicam-induced gastroduodenal lesions.
Puscas I; Puscas C; Coltau M; Pasca R; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):568-72. PubMed ID: 9205767
[TBL] [Abstract][Full Text] [Related]
15. Ebrotidine versus ranitidine in the healing and prevention of relapse of duodenal ulcer. A multicentre, double-blind, parallel, randomized, controlled study.
Tulassay Z; Döbrönte Z; Farkas I; Juhász L; Simon L; Prónai L; Torres J; Márquez M
Arzneimittelforschung; 1997 Apr; 47(4A):551-5. PubMed ID: 9205763
[TBL] [Abstract][Full Text] [Related]
16. Ebrotidine versus ranitidine in the treatment of acute duodenal ulcer. A multicentre, randomized, double-blind, controlled clinical trial.
Matov V; Metchkov G; Krastev Z; Tchernev K; Mitova R; Márquez M; Torres J; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):555-9. PubMed ID: 9205764
[TBL] [Abstract][Full Text] [Related]
17. Gastric mucosal laminin receptor expression with ulcer healing by ebrotidine.
Slomiany BL; Piotrowski J; Czajkowski A; Yotsumoto F; Majka J; Slomiany A
Gen Pharmacol; 1994 May; 25(3):451-5. PubMed ID: 7926589
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-1, interleukin-4 and nitric oxide synthase modulators of gastric mucosal injury by indomethacin: effect of antiulcer agents.
Slomiany BL; Piotrowski J; Slomiany A
J Physiol Pharmacol; 1999 Jun; 50(2):197-210. PubMed ID: 10424717
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol.
Slomiany BL; Piotrowski J; Murty VL; Slomiany A
Gen Pharmacol; 1992 Jul; 23(4):719-27. PubMed ID: 1356875
[TBL] [Abstract][Full Text] [Related]
20. Double-blind crossover study of ranitidine and ebrotidine in gastro-esophageal reflux disease.
Sito E; Thor PJ; M[aczka M; Lorens K; Konturek SJ; Maj A
J Physiol Pharmacol; 1993 Sep; 44(3):259-72. PubMed ID: 8241527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
